Imagin believes that its first product, the enCAGE™ Coil will fundamentally improve the treatment of prostate cancer by reducing the number of patients who suffer from erectile dysfunction and urinary incontinence post-procedure. The Company’s patented technology essentially creates a “Faraday Effect”, enabling the surgeon to preset precise margins to target only the cancer, while avoiding the vulnerable structures that control sexual and urinary function.
Initial clinical results with an early device have been very promising. Imagin plans to refine the product into a production version for submission of an FDA Special 510(k) and subsequent commercial use.
The Company’s next product will be the i/Blue™ Imaging System. It will include advanced, patented and proprietary optics and light sensors. The Company believes that i/Blue will greatly improve the efficiency and accuracy of detecting bladder cancer, potentially leading to a reduction in the recurrence rate of the disease by as much as 33 percent.
Imagin believes that its patented and proprietary technologies will drive improved outcomes and quality of life, while reducing overall costs.